Skip to main content
PRGO
NYSE Life Sciences

Perrigo Q2 2026: $1.02B in Sales, $74.5M Net Income, and a Reaffirmed Full-Year Outlook Amid Turnaround

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$13.28
Mkt Cap
$1.838B
52W Low
$9.225
52W High
$26.99
52W Position info
44% above low
Off High info
51% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PRGO sits 44% above its 52-week low of $9.225.

Summary

Perrigo reported Q2 2026 net income of $74.5 million on $1.02 billion in sales, rebounding from a Q1 loss, and reaffirmed its full-year adjusted EPS outlook. The quarter included a $129.5 million gain from the Dermacosmetics divestiture, while underlying margins remain under pressure.


Key Events · Earnings and Guidance · PRGO

  • Q2 Profitability Restored

    Net income of $74.5 million ($0.53 diluted EPS) versus a $398.6 million loss in Q1 2026, driven by a $129.5 million pre-tax gain on the Dermacosmetics sale and lower restructuring charges.

  • Revenue and Margin Pressure

    Net sales fell 3.2% year-over-year to $1.02 billion; gross margin contracted 370 basis points to 30.7% due to lower volumes and unfavorable mix, partially offset by a $9.6 million tariff refund benefit.

  • Full-Year Guidance Reaffirmed

    Management reaffirmed its 2026 adjusted EPS outlook, signaling confidence that cost-saving programs (Project Energize, Operational Enhancement Program) will offset top-line weakness.

  • Dermacosmetics Divestiture Completed

    The sale closed April 30, 2026, for $362.9 million in net proceeds; $335 million was used to pay down the revolving credit facility, reducing leverage.


Analysis · PRGO · Life Sciences

A sharp reversal from the $398.6 million loss in Q1—driven by a massive goodwill impairment—Perrigo delivered a profitable second quarter with $74.5 million in net income. The quarter benefited from a $129.5 million gain on the sale of the Dermacosmetics Business, which closed in April and generated $362.9 million in proceeds used to pay down debt. Underlying operations remain under pressure: net sales fell 3.2% year-over-year to $1.02 billion, and gross margin contracted 370 basis points to 30.7%. Still, the company reaffirmed its full-year adjusted EPS guidance, signaling confidence in its restructuring and cost-cutting programs. The filing also details a new segment structure, a reinstated executive severance policy, and a new long-term incentive plan—all part of a broader leadership and strategic reset following the CEO's resignation in June.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRGO was trading at $13.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.23 to $26.99. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRGO - Latest Insights

PRGO
Nov 04, 2026, 12:54 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.47
Real-time Price: $16.28 info
Change: -$0.1849 (-1%) info
Market Cap: $2.268B info
PRGO
Nov 04, 2026, 6:44 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.28 info
Change: +$0.1301 (+0.81%) info
Market Cap: $2.268B info
PRGO
Nov 04, 2026, 6:41 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.28 info
Change: +$0.1301 (+0.81%) info
Market Cap: $2.268B info
PRGO
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.70
Real-time Price: $16.28 info
Change: +$0.5801 (+4%) info
Market Cap: $2.268B info
PRGO
Oct 29, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.95
Real-time Price: $16.28 info
Change: +$0.3301 (+2%) info
Market Cap: $2.268B info